Lee Gray

We're thrilled to announce that we're sponsoring an exclusive webinar hosted by The Analytical Scientist on 𝗡𝗶𝘁𝗿𝗼𝘀𝗮𝗺𝗶𝗻𝗲 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗣𝗵𝗮𝗿𝗺𝗮 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆. Don't miss out and save your spot at https://okt.to/ekQvbw Join top experts from AbbVie, Almac, and the FDA for a roundtable discussion on November 14 at 10 am EST | 3 pm GMT! Our distinguished panel will discuss critical topics to help you stay ahead of the latest trends in nitrosamine testing, including: 1️⃣Overcoming the major challenges in detecting nitrosamines 2️⃣Current techniques and technologies 3️⃣How to build a robust method for nitrosamine analysis 4️⃣The impact of recent regulatory changes on the industry 5️⃣Future trends in nitrosamine testing and regulatory landscapes Register today to gain insights from leading voices in pharmaceutical analysis! #NitrosamineTesting #PharmaceuticalAnalysis #pharmaindustry #ScienceForaSaferWorld

16

Achieving diversity in clinical trials is essential in today’s rapidly evolving clinical research landscape, and having a diverse clinical trial team is central to this goal. Download our white paper to explore how #SyneosHealth FSP strategies help build diverse, effective teams: https://lnkd.in/gZr5jxt2 #SyneosHealthLife #WorkHereMattersEverywhere #Clinical Careers

53

Another day, another headline story for MAXWELLIA. This week the Chemist+Druggist report how MAXWELLIA is positioned as a 'switching machine,' as we continue to focus on the reclassification of medicines to improve self care. Read the featured story for insights from our CEO Anna Maxwell, including the future role of over-the-counter medicines. You'll find the link in the comments. #OTC #overthecounter #selfcare #NHS #switching #femalefounder #buywomenbuilt

20

2 Comments

📢"UK planning laws deter investment." says boss of Eli Lilly 💊But the UK has the potential to become a global leader in life sciences 💡Curious to learn more? Listen to our latest podcast with The New Statesman where we discuss: - The key disease areas that need investment including oncology, immunology, obesity and why; - How an unhealthy society impacts the economy; - Who the main competitors are on the global stage, and how the UK can compete; - Prevention is at the heart of the NHS Long Term Plan - what is the role of UK life sciences companies in delivering this? - Our Life Sciences Future50 report, showcasing 50 up-and-coming life sciences companies in the UK The episode features Dan Mahony, chair of the UK BioIndustry Association (BIA); Chi Onwurah newly re-elected MP for Newcastle Central and West and former Shadow Minister for Science, Research and Innovation; and Stephen Aherne, our Pharmaceutical and Life Sciences Leader. https://pwc.to/3WkKH74 #Future50 #LifeSciences #Science #Pharmaceutical #Investment #Equities #Funding

14

Each stage of a #ClinicalTrial is critical to its overall success, explains Parexel. Listen to experts discuss how to best drive value in preclinical development in their latest podcast: https://bit.ly/4c0NBEP

4

🚀 💊 Post-pandemic changes and the introduction of EU-CTR 536/2014 are providing a favorable regulatory environment for drug developers in key strategic regions. In this recording from our recent webinar “Accelerating early phase development in the UK and Germany,” hear from Parexel clinical research experts Amanda Knaggs, Peter Dewland, and Thin Thin Mencarini as they provide an update on recent early-phase regulatory timelines, resulting in trial efficiencies and accelerated approvals for biopharmaceutical companies. Watch the full video here: https://lnkd.in/gUBWcd57 #ParexelBiotech #Regulatory #EarlyPhase #Biopharma

53

Only one day to go to Making Pharmaceuticals 🔬 🧬 Visit our team of specialists on stand 217 where they will be ready and waiting to discuss how #HORIBA can support your application development and the range of innovative solutions available to enable #drugdiscovery, formulation and manufacturing. 🧪 #pharmaceuticals #makingpharmaceuticals 💊

9

In an era of complex #CNS clinical trials, we are generating results for sponsors and CROs. Overwhelmed? Yeah, we know. Discover how our deep scientific expertise and operational know-how will get you where you need to go. https://lnkd.in/ep-fFme5 #ClinicalTrials #ClinicalResearchSites #CNS

14

🌾 𝗪𝗵𝗲𝗮𝘁'𝘀 𝗪𝗲𝗲𝗸𝗹𝘆!! 🌾   #WheatsWeekly - what CDMO updates happened this weeek?   𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗡𝗲𝘄𝘀   ✅ Piramal Group report for the first time in the company’s history, the CDMO’s revenue earned on innovation programs surpassed that of generic projects.   🔐 Pace® Life Sciences complete a successful FDA inspection at it's Oakdale, MN site. 𝗠&𝗔 𝗼𝗳 𝘁𝗵𝗲 𝘄𝗲𝗲𝗸   🤝 Otsuka Pharmaceutical Co., Ltd. agrees to acquire Jnana Therapeutics for $800 million   🤑 MilliporeSigma finish acquisition of Mirus Bio for $600 million 🇺🇸 Cytovance Biologics and Celltheon Corporation partner to deliver complete platform solution for mAbs & proteins   𝗘𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻 𝗼𝗳 𝘁𝗵𝗲 𝘄𝗲𝗲𝗸   🏭 BioIVT opens new cleanroom manufacturing space in Winchester to enhance their new CGT services.   🧬 BeiGene opens flagship US biologics manufacturing and clinical R&D facility 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗼𝗳 𝘁𝗵𝗲 𝘄𝗲𝗲𝗸   💰 Novo Holdings Ltd invest £50 million in Oxford Nanopore Technologies, a UK Listed company behind a new generation of molecular sensing technology based on nanopores.   𝗡𝗲𝘄 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽   👩‍🔬 Martina (Tina) Diekmann is the new President at PHT International, Inc.   Did I miss anything, let me know in the comments! 👇   #CDMO #pharma #biotech

49

It can take years to get a definitive diagnosis for rare diseases with critical gaps in care widening the gap. We sat down with a panel of experts to discuss these gaps and considerations for shortening the time to diagnosis and improving patient support. Watch the full recording of our Rare Disease Revolution panel discussion with Lorna Weir, Stacey Meltzer Wasserman, Katy Palmer, PhD, and Ellen Gordon to find out more about this and other critical topics: https://lnkd.in/d9m49Kq4 #KJT #RareDiseases #PatientVoice #PatientCentricity #MedicalResearch #PharmaceuticalResearch

10

Our latest whitepaper explores lab automation solutions available to CROs and CDMOs ✅ This includes the benefits they can bring and how true infrastructure-level automation can revolutionise the lab experience for everyone - from scientists to clients to patients. Download the ungated content here, no catch ➡️ bit.ly/44tSgwb #CROs #LabAutomation #Whitepaper

7

Almac Diagnostic Services can guide and support your biomarker programmes in relation to IVDR. Learn more from our expert speakers in a recent webinar, hosted by Xtalks, as they discuss their experience with IVDR and describe strategies for solving the specific challenges faced during the IVDR submission process for clinical trial assays being utilised as CDx, allowing global trials to commence and complete in a timely manner. View webinar here: https://hubs.li/Q02D8B1w0 #IVDR #ClinicalTrials #Regulatory #CompanionDiagnostics #IVD #CDx #RegulatoryAffairs

14

Today’s clinical trials are rapidly evolving and highly unpredictable. Together, we'll create and deploy the precise capabilities you need, when and where you need them. With powerful connections, flexible solutions, and seamless acceleration, find out what makes IQVIA FSP different. https://bit.ly/46GFUBZ #FSP #clinicaltrials

17

The 18th annual European Histopathology Forum (EHF) meeting starts tomorrow (Sept. 24) at GSK Stevenage ⏰ Members of our Pharma Services team will be attending and ready to discuss how they support biomarker studies at every stage of R&D, discovery to clinical, so visit our table to learn how partnering with the team can help advance your project! #DigitalPathology #TissueAnalysis #ImageAnalysis #HALOimageAnalysis #IndicaLabs

10

Achieving diversity in clinical trials is essential in today’s rapidly evolving clinical research landscape, and having a diverse clinical trial team is central to this goal.   Download our white paper to explore how #SyneosHealth FSP strategies help build diverse, effective teams: https://lnkd.in/gqBWqFAy   #SyneosHealthLife #WorkHereMattersEverywhere #Clinical Careers

3

Why Partnering with a Specialist in Quality & Regulatory Recruitment is Crucial for Senior Roles in Pharma, Biotech, and Medical Devices In highly regulated sectors like pharma, biotech, and medical devices, finding top talent for senior Q&R roles is essential. Here’s why partnering with a specialist like Stirling Q&R is invaluable: 1. **Industry Expertise**: Specialists understand regulatory requirements and quality standards, ensuring they find candidates with the right qualifications and mindset. 2. **Access to Top Talent**: With extensive networks, specialists can tap into a pool of highly qualified candidates, including those not actively seeking new jobs. 3. **Time Efficiency**: Specialists streamline the recruitment process by pre-screening candidates, saving your company time and resources. 4. **Cultural Fit**: Specialists are adept at assessing cultural fit, crucial for long-term success and retention. 5. **Mitigating Risk**: Leveraging their expertise, specialists ensure a thorough vetting process, reducing the risk of hiring the wrong candidate. 6. **Regulatory Insight**: Specialists stay updated on regulatory changes, ensuring your company remains compliant and competitive. Partnering with a specialist like Stirling Q&R is a strategic move that drives success in a competitive, regulated market.

1

🔬 We are back with another “Ask a Virologist”! Cell & gene therapy manufacturing is challenging, and a lot of effort goes into establishing a production platform. At Virica we understand the need to enhance CGT productivity without disrupting your current platform. This week, Keara Sutherland, talks about how our Viral Sensitizer (VSEᵀᴹ) can be: ✔ Seamlessly integrated into your production process without disruption. ✔ Rapidly metabolized leaving no residues. 👇 Check out the video to know more! In case you missed the other videos in the series! Our unique mode of action: https://lnkd.in/dusFXNwK What makes VSEs broadly applicable to various virus and cell line combinations and applications: https://lnkd.in/dHxMEGtt Follow along as we highlight the unique aspects of VSEs! 👉 If you find this series valuable subscribe to our newsletter for all things CGT! https://lnkd.in/d-rf3XVX #biomanufacturing #innovation #QandAs #askavirologist

26

Join Matthew Hewitt's presentation, “Fast technology coupled with deliberate regulatory: How can the field adapt new guidance to meet therapeutic demand?” CAR-TCR Summit Series As the number of CGT market approvals accelerates, Matt will discuss challenges in manufacturing and address how working collaboratively with partners and regulators aids in tackling the pain points of therapeutic development and clinical trial design. Don't miss this insightful session on regulatory guidance. https://okt.to/KTZMwk #cartcr #cgtdevelopment #celltherapy

17

Our survey shows biotech companies are more confident in their overall success in 2024. They can build on this confidence with more strategic R&D to optimise impact and efficiency. ICON Biotech President Chris Smyth shares insights from our recent sector survey along with considerations for biotech as they recalibrate their approaches to improving trial designs, timelines and data strategies. Read the article here: https://ow.ly/YjIL50SuBg9

230

3 Comments